Year in Reivew by Carol Langford ACR 2022 Tofacitinib: all Jak 1,2,3 (T for Three) Baricitinib: Both 1,2 (B for both) Upadacitinib: 1 (U for Uno or 1) Deucravacitinib: TYK2 i #5 new approval for JAKi Tofacitibinb: AS Upa: PsA, AS, nr-axSpA Deucravacitinib: Psoriasis, PsA, SLE (not FDA approved, but in publication) #IL-6 : JAK1 and 2 #Type 1 IFN: Jak1 and Tyk 2 #FDA Approval JAKi - 5 new approval as noted above IL-23i - Risankizumab for PsA (previously approved was Guselkumab) #Bimekisumab: IL17Aand IL17F inhibitor (nrAxSpA, AS, PsA, PsO) New studies Aaryanepallis4 |
Rheumatology >